A decade has passed since the first topical prostaglandin analog was prescribed to reduce
intraocular pressure (IOP) for the treatment of glaucoma. Now four prostaglandin analogs …

Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP)
in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive …

Glaucoma is the leading cause of irreversible blindness, resulting from an increase in
intraocular pressure (IOP). IOP is the only modifiable risk factor of glaucoma and is …

The majority of blinding conditions arise due to chronic pathologies in the retina. During the
last two decades, antibody-based medicines administered by intravitreal injection directly …

Purpose.: This study tested the hypothesis that intraocular pressure (IOP) elevations,
induced by controlled increase of intraocular volume, are correlated with the biomechanical …

Purpose: The aim of this study was to test the hypothesis that nitric oxide (NO) mediates a
pressure-dependent, negative feedback loop that maintains conventional outflow …

Purpose.: To study the effect on intraocular pressure (IOP) of a sudden increase in blood
pressure (BP) and of changes in partial pressure of CO 2 (pCO 2). Methods.: Two …

Primary open-angle glaucoma (POAG) with complex pathogenesis is one of the many major
causes of blindness. It is widely accepted that the major cause of POAG is the dysregulation …

This study aimed to characterize a technique that assesses the outflow facility (C) efficacy of
five kinds of IOP-lowering drugs commonly used clinically in enucleated porcine Eyes. Eyes …

US9506907B2 - Bioengineered human trabecular meshwork for biological applications -
Google Patents US9506907B2 - Bioengineered human trabecular meshwork for biological …